Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merus N.V. CS (MRUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 254,800
  • Shares Outstanding, K 22,751
  • Annual Sales, $ 15,370 K
  • Annual Income, $ -82,610 K
  • 36-Month Beta -0.08
  • Price/Sales 10.73
  • Price/Cash Flow N/A
  • Price/Book 2.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.93
  • Number of Estimates 2
  • High Estimate -0.89
  • Low Estimate -0.96
  • Prior Year -0.86
  • Growth Rate Est. (year over year) -8.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.02 +0.64%
on 02/22/19
13.36 -16.99%
on 01/23/19
-1.21 (-9.84%)
since 01/22/19
3-Month
11.00 +0.82%
on 12/04/18
17.75 -37.52%
on 01/08/19
-3.89 (-25.97%)
since 11/21/18
52-Week
11.00 +0.82%
on 12/04/18
26.74 -58.53%
on 07/10/18
-6.88 (-38.29%)
since 02/22/18

Most Recent Stories

More News
Merus to Participate in Guggenheim Healthcare Talks Idea Forum

UTRECHT, Netherlands, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics(R), innovative full-length human bispecific antibody therapeutics,...

MRUS : 11.09 (-0.98%)
Amarin Down on Lower '19 View, Posts Preliminary '18 Results

Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.

AMRN : 19.87 (+14.00%)
MRUS : 11.09 (-0.98%)
NCNA : 11.71 (+1.30%)
MBRX : 1.38 (+0.73%)
Merus Announces IND Clearance for MCLA-145

MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137

MRUS : 11.09 (-0.98%)
INCY : 84.85 (+1.82%)
ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology

MRUS : 11.09 (-0.98%)
Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China

Merus to retain all global rights outside of China

MRUS : 11.09 (-0.98%)
Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update

Clinical milestones for four lead Biclonics(R) programs expected in 2019

MRUS : 11.09 (-0.98%)
Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals

Merus and Regeneron to cross-license patents relating to certain antibody generation platform technologies

MRUS : 11.09 (-0.98%)
Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRUS : 11.09 (-0.98%)
Merus to Present at the Jefferies 2018 London Healthcare Conference

UTRECHT, The Netherlands, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics(R)), today...

MRUS : 11.09 (-0.98%)
Report: Developing Opportunities within Spotify Technology SA, Vornado Realty Trust, Merus N.V, Teekay Tankers, PagSeguro Digital, and Liberty Oilfield Services -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Spotify Technology SA (NYSE:SPOT),...

BDFC : N/A (unch)
TNK : 1.09 (+2.83%)
SPOT : 151.19 (+1.80%)
VNO : 68.89 (+0.69%)
MRUS : 11.09 (-0.98%)
PAGS : 26.12 (+14.31%)
LBRT : 16.99 (+0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade MRUS with:

Business Summary

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is...

See More

Key Turning Points

2nd Resistance Point 11.75
1st Resistance Point 11.42
Last Price 11.09
1st Support Level 10.89
2nd Support Level 10.69

See More

52-Week High 26.74
Fibonacci 61.8% 20.73
Fibonacci 50% 18.87
Fibonacci 38.2% 17.01
Last Price 11.09
52-Week Low 11.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar